Showing results (201-210 of 212) with videos related to

Sort By:
Pageof 22
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Journal of Neuromuscular Diseases|July 10, 2023
Closing the Gap - Detection of 5q-Spinal Muscular Atrophy by Short-Read Next-Generation Sequencing and Unexpected Results in a Diagnostic Patient CohortStephanie Kleinle, Veronika Scholz, Anna Benet-Pagés, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
JNCI Cancer Spectrum|January 9, 2025
Changes in breast cancer risk associated with benign breast disease from 1967 to 2013Amy C Degnim, Karthik Ghosh, Robert A Vierkant, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2017
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitorsJun Liang, Sharada Labadie, Birong Zhang, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Pageof 22